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Inactivation of the tumor suppressor gene
von Hippel-Lindau (VHL) in granulocytes
contributes to development of liver
hemangiomas in a mouse model
Hannah L. Bader1* and Tien Hsu1,2*
Abstract
Background: Mutations in the tumor suppressor gene von Hippel-Lindau (VHL) underlie a hereditary cancer
syndrome—VHL disease—and are also frequently observed in sporadic renal cell carcinoma of the clear cell type
(ccRCC). VHL disease is characterized by malignant and benign tumors in a few specific tissues, including ccRCC,
hemangioblastoma and pheochromocytoma. The etiology of these tumors remains unresolved.
Methods: Conditional inactivation of the VHL gene in mouse (Vhlh) was generated to examine the pathophysiological
role of the VHL gene function. Specific cell populations were isolated by fluorescence-activated cell sorting (FACS) and
bone marrow transplants were performed to identify the Vhlh-inactivated cells responsible for the phenotype.
Results: Previously we showed that inactivation of Vhlh in a subpopulation of kidney distal tubule cells resulted in
hyperplastic clear-cell lesions and severe inflammation and fibrosis. Here, we show that this knockout mouse strain also
develops Hif-2α-dependent vascular overgrowth (hemangioma) and extramedullary erythropoiesis in the liver. However,
Vhlh inactivation was not detected in the liver parenchyma. We instead demonstrate that in these mice, Vhlh is
inactivated in liver granulocytes and that hemangiomas are partially rescued in knockout mice reconstituted with
wild-type hematopoietic stem cells, indicating the involvement of bone-marrow-derived leukocyte. Interestingly,
bone marrow from knockout mice failed to generate the liver phenotype in wild-type recipients, suggesting that
an additional cell type that is not derived from the bone marrow is involved in the development of the hemangioma
phenotype.
Conclusion: These results support the idea that the development of a full-blown VHL disease phenotype requires
inactivation of the VHL gene not only in the tumor proper, but also in the stromal compartment.
Keywords: von Hippel-Lindau, Hypoxia-inducible factor 2 alpha, Hemangioma, Placental growth factor, Extramedullary
erythropoiesis, Hemangioblastoma, Neutrophil, Angiogenesis
Background
Patients with VHL disease are heterozygous for VHL
mutations, and develop tumors when the function of the
remaining wild-type VHL allele is lost via somatic muta-
tion or epigenetic silencing [1]. VHL tumors, which can
occur in several different tissues, are characterized by
hypervascularity and a clear cell appearance in histological
preparations. VHL mutations are also frequently observed
in sporadic renal cell carcinoma (ccRCC). In addition,
specific VHL missense mutations have been described that
do not cause tumors, but result instead in recessive poly-
cythemia, a disease characterized by an overproduction of
erythrocytes [2–4].
VHL protein (pVHL) is an essential negative regulator
of the hypoxia-inducible factor (HIF), a transcription
factor induced by low oxygen tension [5]. HIF induces a
metabolic switch from oxidative phosphorylation to gly-
colysis, which is essential for cell survival under hypoxic
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conditions. HIF also promotes angiogenesis and erythropoi-
esis through induction of cytokines such as vascular endo-
thelial growth factor (VEGF) and erythropoietin (EPO).
The active HIF transcription factor is a dimer consisting of
an α and a β subunit [1, 5]. The β unit—known as HIF-1β
or ARNT (arylcarbon receptor nuclear translocator)—is
ubiquitously and constitutively expressed. In contrast, the
HIF-α subunits (HIF-1α, HIF-2α and HIF-3α) are regulated
by oxygen tension. Under normoxic conditions, HIF-α is
hydroxylated. The hydroxylated form is recognized by an
ubiquitin ligase and undergoes ubiquitination, followed by
proteasome-mediated degradation. Hydroxylation is oxygen
dependent, and is inhibited under hypoxic conditions.
Thus, hypoxia leads to stabilization of the HIF-α protein,
allowing formation of the dimeric HIF transcription factor
and transactivation (or repression) of HIF responsive genes.
pVHL is the substrate recognition component of the
multimeric ubiquitin-ligase complex that mediates HIF-α
ubiquitination [1, 5]. VHL gene inactivation therefore
leads to normoxic stabilization of HIF-α and inappropriate
activation of the HIF transcription factor. The formation
of VHL tumors is thought to be driven in large part by
genes induced or suppressed by HIF [5]. However, loss of
HIF-independent functions of VHL, and mutations of add-
itional tumor suppressor genes, likely also contribute to
tumorigenesis [1, 6, 7]. Recent animal model and cancer
genome studies have indicated that VHL mutations are
necessary but insufficient for tumorigenesis [6, 8–10].
Such second and even third hits conceivably can be add-
itional genetic or epigenetic changes within the same cells,
or can be within a separate cell population that contrib-
utes to the formation of tumor microenvironment. The
requirement for additional tumor suppressor gene(s) in
ccRCC formation was supported by the construction of
Vhlh (mouse allele of VHL)-Bap1 double knockout [11].
BAP1 gene mutations have been observed in ~10 % of
ccRCC samples [9, 10]. Vhlh-Bap1 double knockout gen-
erated clear-cell lesions that resemble carcinoma [11]. On
the other hand, mutations in the cancer stromal cells, in-
cluding those of the well-known tumor suppressor genes
p53 and PTEN, have been documented that contribute to
cancer progression {reviewed in [12]}. It is therefore
possible that in VHL patients, VHL inactivation could
also occur in the tumor microenvironment (stroma) in
addition to the tumor itself.
One of the most frequently observed tumors in VHL
patients besides ccRCC is hemangioblastoma, a highly
vascularized tumor with extramedullary hematopoiesis
that occurs in the central nervous system and the retina
[13]. Hemangioblastomas cause considerable morbidity
and mortality despite being benign. Hemangioblastomas
are sometimes referred to as vascular tumors; however,
biallelic inactivation of VHL was detected in the stromal
compartment of the vascular tumors [14–16], which also
have a clear cell appearance. Vascular overgrowth is there-
fore likely induced by pro-angiogenic cytokines released by
these “stromal cells.” In addition, hemangioblastomas fre-
quently contain foci of extramedullary erythropoiesis and
the VHL− stromal cells exhibit multipotency that may be of
embryonic origin [17–19]. There are no mouse models that
recapitulate hemangioblastoma. However, several VHL
mouse models develop hemangiomas—an overgrowth
of irregularly shaped and leaky blood vessels—in the
liver [20–23]. Hemangiomas have been observed in the
liver of germline Vhlh+/- mice [20] and in mosaic Vhlh
biallelic deletion mice induced by conditional β-actin-
driven Cre [21]. These two models contain heterozygous
and homozygous, respectively, Vhlh mutants in most cell
types, including hepatocytes and endothelial cells. More
interestingly, liver hemangiomas were also observed in
PEPCK-Cre driven Vhlh knockout, which inactivates Vhlh
in renal proximal tubule cells and in ~20 to 30 % of hepato-
cytes [20, 22]. Likely due to early mortality, full-blown
hemangiomas were not observed when a more hepatocyte-
specific Cre driver, Albumin-Cre, was used to inactivate
Vhlh; nonetheless, numerous blood-filled vascular cavities,
and foci of increased vascularization within the hepatic par-
enchyma were observed [20, 22]. Inactivation of Vhlh in
hepatocytes with PEPCK-Cre or Albumin-Cre also led to
erythrocytosis—overproduction of erythrocytes—due to in-
creased expression of Epo [20, 22], although hemangioma-
associated extramedullary erythropoiesis—as observed in
hemangioblastoma—was not observed. Hif-2α was found
to mediate up-regulation of erythropoietin and multiple
pro-angiogenic cytokines in these mouse models, and in-
activation of Hif-2α or Hif-1β/Arnt, but not Hif-1α, rescued
hemangiomas in PEPCK-Cre or Albumin-Cre driven Vhlh
knockout mice [22, 24].
Previously we showed that inactivation of Vhlh in a sub-
population of kidney distal tubules, using the HOXB7-Cre
driver, resulted in Hif-1α-dependent hyperplastic clear-cell
lesions and severe inflammation and fibrosis [25]. Here,
we report that the same HOXB7-Cre driven Vhlh condi-
tional knockout mice also developed liver hemangiomas
as well as extramedullary erythropoiesis. Interestingly, in
contrast to the previous mouse models, we did not detect
Vhlh inactivation in hepatocytes. Instead, Vhlh inactiva-
tion was detected in liver granulocytes in the knockout
mice. In support of a myeloid component in the develop-
ment of hemangiomas in the liver, reconstitution of the
knockout mice with wild-type hematopoietic stem cells
partially rescued the hemangioma phenotype. Further ana-
lysis showed that the granulocyte population contained
the Vhlh deleted allele. In addition, granulocytes (neutro-
phils) in livers of the HOXB7-Cre driven Vhlh knockout
mice were found to over-express placental growth factor
(PlGF) that has been shown to promote angiogenesis.
Thus, this mouse model supports the notion that a bone
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marrow-derived stromal component with VHL loss-of-
function contributes to the development of the full extent
of the VHL disease phenotype.
Methods
Animal protocol and mouse strains
All of the procedures were conducted in accordance
with the US Public Health Service Policy on Humane
Care and Use of Laboratory Animals. Mice used in these
studies were maintained in Boston University Medical
Center facility according to protocols approved by the
Institutional Animal Care and Use Committee. Mouse
strains used were in C57BL/6 background and have been
described previously [25]. For generation of bone marrow
chimeras, B6.SJL-Ptprca Pepcb/BoyJ (“B6 CD45.1”) as well
as RosaLacZ was purchased from Jackson Laboratories
(Bar Harbor, Maine, USA).
Reagents
Phosphate-buffered saline (PBS), Dulbecco’s phosphate-
buffered saline (DPBS), Dulbecco’s modified eagle medium
(DMEM) and HEPES were obtained from Gibco/Life
Technologies (Carlsbad, CA, USA). Fetal bovine serum
(FBS) was obtained from Hyclone (Logan, UT, USA). Ster-
ile 0.5 M EDTA stock solution, pH7.5, was obtained from
Boston Bioproducts (Ashland, MA, USA). Fluorescence-
activated cell sorting (FACS) buffer was prepared as
follows: 0.5 % FBS/2 mM EDTA in DPBS. Red blood
cell lysis buffer, Fc-block and antibodies for flow cytom-
etry (except anti-CD45 antibody) were obtained from
eBioscience (San Diego, CA, USA). Cell strainers (40 μm
or 70 μm) were obtained from ThermoFisher Scientific
(Waltham, MA, USA).
Histology and immunohistochemistry
Livers were fixed overnight in 10 % neutral buffered
formalin and were embedded in paraffin. 4 μm thick par-
affin sections were stained with hematoxylin and eosin
(H&E) according to standard procedures. For immunohis-
tochemistry, 4 μm thick paraffin sections were dewaxed,
and heat mediated antigen retrieval was performed with
citrate buffer, pH 6, for 40 min. Endogenous peroxidase
was quenched by incubating sections for 15 min in metha-
nol with 0.3 % H2O2 or peroxidase block (Peroxidased 1,
Biocare Medical, Concord, CA). Endogenous biotin was
blocked with avidin-biotin blocking kit (Vector Laborator-
ies, Burlingame, CA, USA), followed by 30 min blocking
with 3 % or 10 % (GFP stain) normal goat serum (Sigma-
Aldrich, St. Louis, MO) in PBS. Staining and washing was
performed with PBS, 0.05 % Tween 20 (Sigma-Aldrich).
Sections were incubated overnight at 4 °C with primary
antibody (1:50 rat anti-CD45, clone 30-F11, Molecular
Probes/Life Technologies, Carlsbad, CA, USA; 1:100 rabbit
anti-mouse Plgf, Origene/Acris Antibodies, Rockville, MD,
USA; 1/500 chicken anti-GFP, Abcam) and incubated for
45 min with appropriate biotinylated secondary antibody
(Vector Laboratories) at 1/500 (rabbit and chick secondary)
or 1/1000 (rat secondary). After washing 3 × 5 min (CD45)
or 4 × 15 min [placental growth factor Plgf), GFP], sections
were incubated for 45 min with streptavidin-conjugated
horseradish peroxidase (Invitrogen/Zymed, Carlsbad, CA,
USA) at 1/1000 (CD45 stain) or with ABC Elite Kit (Vector
Laboratories; Plgf, GFP stain). Sections were washed again
for 3 × 5 min (CD45) or 4 × 15 min (Plgf, GFP) and were
incubated for 5–10 min with peroxidase substrate (DAB,
Vector Laboratories). Sections were counterstained with
hematoxyline and mounted with permount (ThermoFisher
Scientific).
Preparation of single cell suspensions from liver
Livers were dissected out taking care to minimize bleeding,
and were rinsed with DPBS to wash off excess blood. For
wild-type samples, small pieces of liver were dissected out
from the left and median lobe (lobe encasing the gallblad-
der). For knockout samples, liver pieces containing hem-
angiomas were dissected out. In some cases hemangioma
tissue was pooled from two mice to obtain enough material.
Next, liver tissue was minced and resuspended in 5–10 ml
digestion buffer consisting of ice-cold DMEM with
5 mg/ml (or 800 U/ml) collagenase (trypsin-free Colla-
genase, CLS-4, Worthington Biochemical Corporation,
Lakewood, NY, USA) and 20 mM HEPES. Digestion
was performed at 4 °C for 1–1.5 h in 5-ml round bot-
tom polypropylene tubes with overhead rotation. The
digest was then diluted 2-fold in FACS buffer, EDTA
was added to a final concentration of 2 mM, and the
cell solution was strained through a 70-μm strainer.
Next, cells were pelleted at 250 xg for 8 min at 4 °C,
and resuspended in ice-cold red blood cell lysis buffer
(from eBioscience, San Diego, CA, USA). Red blood cell
lysis was performed for 3 min on ice. After washing,
liver cells were resuspended in FACS buffer and stained
as described below.
Flow cytometry and FACS
Staining was carried out in 1.5-ml tubes. For wash steps,
cells were pelleted in a tabletop centrifuge (250 xg at 4 °C
for 5 min). After treatment with red blood cell lysis buffer
(see preparation of single cell suspensions), cells were re-
suspended in ice-cold FACS buffer and concentration was
adjusted to 1 × 106 cells–5 × 106 cells per 100 μl. Cells were
incubated with Fc-block (1:100) for 5 min on ice, before
adding primary antibodies. After cells were incubated for
20 min on ice with primary antibodies, live/dead stain was
performed. For propidium iodide staining, cells were
washed once with 1 ml FACS buffer, and resuspended in
FACS buffer with 1 μg/ml propidium iodide (1 mg/ml stock
solution obtained from Life Technologies). Cells were then
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transferred to round bottom polypropylene tubes for sort-
ing/analysis (no washing required after propidium iodide
step). For staining with Aqua Blue Live/Dead solution (Life
Technologies), cells were resuspended in 1 ml FACS buffer
with 1:1000 of Aqua Blue stock solution (Life Technologies;
stock solution prepared according to instructions of manu-
facturer) and were incubated for 15 min at 4 °C with over-
head rotation (washing after antibody staining and live/
dead staining in one step). Subsequently, cells were washed
once with 1 ml FACS buffer, and were resuspended in
FACS buffer and transferred to round bottom polypropyl-
ene tubes for sorting/analysis; cell suspensions were filtered
through a 40-μm strainer. For sorting of CD45+ cells, cells
were stained with CD45-APC (1:200; Molecular Probes/Life
Technologies), followed by propidium iodide stain (Life
Technologies). For quantification and sorting of erythrocyte
progenitors, cells were triple stained with the following
antibodies: CD45-Percp-Cy5 1:200, TER119-APC 1:100
and CD71-PE 1:200; followed by Aqua Blue Live/Dead stain
(Life Technologies). For determination of chimerism in
peripheral blood, cells were double-stained with CD45.1-PE
and CD45.2-APC at 1:100 and dead cells were gated out
according to size (FSC vs SSC plots). Cell sorting and ana-
lysis of liver samples was performed with the FACS Aria II
SORP (Becton-Dickinson) or Beckman-Coulter Moflo.
Liver colony forming unit assay
Livers were dissected out taking care to minimize bleed-
ing, and were rinsed with 20 ml DPBS to rinse off excess
blood. Subsequently, homogenization was performed as
described above but without collagenase treatment. After
passing the cell suspension through a 70-μm strainer,
cells were pelleted (250 xg at 4 °C for 8 min) and resus-
pended in 20 ml DPBS containing 2 % FBS. For cell
counting, a small aliquot was stained with an acridine
orange and propidium iodide solution (AO/PI solution,
Nexcelcom, Lawrence, MA, USA) according to the in-
structions of the manufacturer, and counted with the
cellometer (Nexcelcom). 4.8 × 105 live cells in 300 μl
DPBS were then added to 3 ml of MethoCult GF M3434
(Stem Cell Technologies, Vancouver, BC, Canada) and
plated out into two 3-cm tissue culture dishes, following
instructions of the manufacturer. BFU-E colonies per
plate were quantified in a blinded fashion after 7–8 days,
and were averaged for each sample (2 plates per sample).
β-galactosidase staining of organs
Chemicals for staining were obtained from Thermo-
Fisher Scientific. Livers and kidneys were fixed in 4 %
paraformaldehyde in PBS for ~4 h at room temperature.
Organs were then washed (3 × 30 min) with wash buffer
(0.1 M NaH2PO4, 0.1 M Na2HPO4, 2 mM MgCl2, 0.01 %
deoxycholate, 0.02 % NP-40) and stained overnight at 4 °C
with staining buffer (wash buffer with 5 mM ferrocyanide,
5 mM ferricyanide and 1 mg/ml 5-bromo-4-chloro-3-indo-
lyl-β-D-galactopyranoside (X-Gal). Organs were photo-
graphed, post-fixed for 15 min with 4 % paraformaldehyde
in PBS, and were embedded in paraffin. 4 μm thick paraffin
sections were prepared and counter-stained with Nu-
clear Fast Red (Vector Laboratories) and analyzed for
β-galactosidase staining.
Isolation of genomic DNA and polymerase chain reaction
(PCR) for detecting Vhlh deletion
DNA from liver tissue was obtained using the DNAeasy
blood and tissue kit (Qiagen, Valencia, CA, USA) ac-
cording to instructions of the manufacturer. Sorted cells
(10,000-500,000) were pelleted in a table top centrifuge
(300 xg, 5 min), frozen in <100 μl DPBS with 2 % FBS,
and stored at −80 °C. Subsequently, DNA was obtained
with the Qiamp Micro DNA kit (Qiagen) following the
protocol for DNA isolation from small amounts of
blood. Vhlh primers for detection of the Vhlh flox allele
and wild-type allele have been described before [22]; se-
quences are as follows: Vhlh-wt/flox forward primer
(FW1), ctaggcaccgagcttagaggtttgcg; Vhlh-wt/flox reverse
primer (Rev1), ctgacttccactgatgcttgtcacag. PCR products
are ~290 bp (wt allele) and 460 bp (floxed allele). The
site of the forward primer is lost upon recombination;
the Vhlh-wt/flox primers therefore cannot amplify the
recombined/deleted Vhlh allele. Generic primers were
used to detect Cre: FW, atccgaaaagaaaacgttga; Rev, atc-
caggttacggatatagt; Cre-PCR product is ~700 bp. Vhlh de-
letion primers were designed as follows: the forward
primer (FW2) is situated downstream of the second
HindIII restriction site, and upstream of the NdeI re-
striction site within the 5′ untranslated sequence of the
murine Vhlh gene. The reverse primer (Rev2) is situated
downstream of the HindIII restriction site within the
first intron of the murine Vhlh gene [20]. The sequences
are as follows: Vhlh-del forward primer (FW2): ggaac-
catctcttctctgatagagc; Vhlh–del reverse primer (Rev2):
gctggttgcttcagacacaatcttg. The Vhlh del primers flank
exon 1 (see Fig. 4c). In the presence of exon 1, the se-
quence is very long (~4 kb) and is therefore not amplified
under stringent PCR conditions (e.g., short extension
time). In the presence of Cre, exon 1 is excised, resulting
in a much shorter sequence, allowing amplification of the
recombined/deleted Vhlh allele. The Vhlh-del PCR prod-
uct is ~ 800 bp. Identity of the product was confirmed by
sequencing.
Serum collection and ELISA for erythropoietin
Peripheral blood was collected in heparinized microca-
pillaries (ThermoFisher Scientific), and was transferred
into collection tubes with clotting activator (BD Micro-
tainer SST, Becton Dickinson, Waltham, MA, USA).
Blood was incubated for ~5–10 min at room temperature,
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and centrifuged at full speed in a table-top centrifuge. The
serum (corresponding to supernatant) was collected and
stored at −80 °C for up to 4 months. Subsequently,
erythropoietin ELISA was performed with Quantikine
erythropoietin ELISA kit (RD systems Inc, Minneapolis,
MN, USA) according to instructions of the manufacturer.
Preparation of cDNA and quantitative PCR
Liver RNA was isolated using Trizol in combination with
Purelink RNA Mini kit (Invitrogen/Life Technologies)
according to instructions of manufacturer. DNA was
digested with on-column DNAse I digestion kit (Invitro-
gen/Life Technologies) according to instructions of manu-
facturer. Sorted cells (~20,000) were pelleted, resuspended
in Quiazol (Qiagen) and stored at −80 °C. Subsequently,
RNA was purified using the miRNAeasy Kit (Qiagen)
according to instructions of the manufacturer. After elu-
tion, RNA from sorted cells was dried in GenTegra™-RNA
tubes (GenTegra, Pleasanton, CA, USA) and was resus-
pended in ~5 μl of water. Liver RNA (1 μg) or entire
RNA obtained from ~20,000 sorted cells was reverse
transcribed with AMV First Strand cDNA kit (liver) or
Protoscript II first strand synthesis kit (sorted cells; both
kits from New England Biolabs, Ipswich, MA, USA) ac-
cording to instructions of the manufacturer. Real-time PCR
was performed with Power SYBR Green Mastermix (Ap-
plied Biosystems/Life Technologies) using a StepOne Real
time PCR system (Applied Biosystems/Life Technologies).
The following primers from the Universal Probe Library
(Roche/Life Technologies) were used: 18 s forward primer,
gcaattattccccatgaacg; 18 s reverse primer, gggacttaatcaacg
caagc; erythropoietin forward primer, ccctgctgcttttactctcc;
erythropoietin reverse primer, gggggagcacagaggact; prolyl-
hydroxylase 3 (Phd3) forward primer, tgtctggtacttcgatgctga;
reverse primer, agcaagagcagattcagtttttc.
Hoechst staining and bone marrow transplant
Staining with Hoechst 33342 (Life Technologies) was
performed as described previously [26, 27], with the fol-
lowing modification: to increase the yield, Hoechst was ti-
trated so that cells were understained (to achieve a
Hoechst negative side population of ~1 %). Subsequently,
only the least Hoechst positive cells (comprising 0.2–0.5 %
of all cells) were sorted, and 1000 SP were used per recipi-
ent; 3 × 105 unfractionated bone marrow cells were co-
transplanted to improve survival. Recipients were lethally
irradiated one day before transplantation with a split dose
of 14 gray (2 month old recipients) or 11 gray (4 week old
recipients) separated by 2 h. For 2 weeks after the trans-
plant, starting with the day of the transplant, recipients
received antibiotics in the drinking water. To examine
chimerism using flow cytometry, peripheral blood was
collected in heparinized microcapillaries (ThermoFisher
Scientific). Blood samples (~100 μl) were then transferred
to 1.5 ml tubes containing 100 μl DPBS with 2 mM
EDTA. 1 ml of red blood cell lysis buffer was added to
samples, and red blood cell lysis was carried out 5 min at
room temperature. After adding 10 ml of ice cold FACS-
buffer, samples were transferred to 15 ml centrifuge tubes
and were centrifuged (8 min, 250 g, 4 °C). Cells were then
resuspended in 100 μl FACS-buffer, and stained with anti-
bodies for flow cytometry (see above).
Statistical analysis
Unpaired, two-tailed t-tests were performed; where ne-
cessary, Welch’s correction for unequal variances was
applied. All analyses were performed using GraphPad
Prism Software (La Jolla, CA, USA). For group compari-
sons, p-values were calculated with GraphPad prism
software, and false discovery rate (FDR) was calculated
manually using Bonferroni post-test or Benjamini and
Hochberg FDR formula.
Results
Hepatic hemangioma phenotype in the HOXB7-Cre driven
Vhlh knockout mice
HOXB7-Cre is widely used to target the collecting ducts
of the kidney [28, 29]. However, we recently found that
this Cre driver is also expressed in a subset of distal tu-
bules in the kidney cortex. Conditional inactivation of
Vhlh using this Cre driver resulted in fully penetrant
hyperplasia, cysts, clear-cell lesions, inflammation and fi-
brosis in the kidney, with the hyperplastic lesions arising
primarily from Tamm-Horsfall positive distal tubules [25].
Interestingly, these HOXB7-Cre; Vhlhfl/fl mice also de-
veloped hemangiomas in the liver starting at 3 weeks of
age. The diseased liver showed an overgrowth of irregu-
larly shaped, abnormally large and leaky blood vessels
(compare Fig. 1a, b). Erythrocytes (Fig. 1b) and leuko-
cytes (Fig. 1c) accumulated within the hemangiomas,
based on pathologist’s assessment. Leukocytes were also
identified adjacent to hemangiomas by immunohisto-
chemistry for CD45-expressing cells (Fig. 1d; based on
pathologist’s assessment). Older mice (>3 months) add-
itionally developed fibrotic lesions (Fig. 1e, f ), indicating
involvement of an immune component. The develop-
ment of hemangioma starts between 3 and 4 weeks of
age and the penetrance reached 90 % at 6 weeks (Fig. 1g).
In contrast, the development of kidney lesions in this
knockout mouse strain begins at 8 weeks and becomes
fully penetrant at 12 weeks [25].
Extramedullary erythropoiesis in the liver of HOXB7-Cre
driven Vhlh knockout mice
Hemangioblastoma associated with the VHL disease often
presents with extramedullary erythropoiesis [17]. Indeed
in our model, quantification of erythrocyte progenitors in
livers of wild-type and knockout mice by flow cytometry
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(TER119 + CD71+; pooled data from >2 month old mice;
Fig. 2a) indicated that there was a >10-fold increase in
erythrocyte progenitors in livers of knockout mice. The
extent of increase in TER119 + CD71+ cell number is in
agreement with colony forming unit assay that function-
ally defines erythrocyte progenitors (Fig. 2b). Epo is a key
cytokine that promotes erythropoiesis, including the for-
mation of BFU-E and the subsequent differentiation steps
to form erythrocytes [30]. Its expression is induced under
hypoxic conditions by HIF transcription factor and in
VHL mutant cells. We indeed demonstrated that the in-
creased number of erythrocyte progenitors correlated
with over-expression of Epo: Epo mRNA was up-
regulated in liver of the knockout mice (Fig. 3a), and
Epo protein was increased in the serum (Fig. 3b) in the
Vhlh knockout mice. However, Vhlh deletion is not
present in these progenitor cells (Fig. 3c), indicating
that a non-erythroid Vhlh− component is responsible
for inducing extramedullary erythropoiesis.
Hepatic phenotypes of HOXB7-Cre driven Vhlh knockout
mice are Hif-2α-dependent
Previous conditional knockout mice with Vhlh inacti-
vation in hepatocytes developed liver hemangiomas
and erythrocytosis, but no hemangioma-associated
extramedullary erythropoiesis [22, 24]. In those mouse
models, hemangiomas and erythrocytosis were rescued
by Hif-2α inactivation. We therefore examined the
effects of Hif-2α inactivation on the phenotypes ob-
served in our mouse model by generating HOXB7-Cre;
Vhlhfl/fl; Hif-2αfl/fl double knockouts. Hif-2α knockout
rescued elevated serum Epo (Fig. 3b) as well as extra-
medullary erythropoiesis, as assessed with colony
forming unit assay (Fig. 2b). Hif-2α inactivation also
ameliorated the hemangioma phenotype. The onset of
hemangiomas was delayed (25 % vs 90 % at 6 weeks),
and the number of hemangiomas per liver was signifi-
cantly reduced in 2 to 3-month old double knockouts
(Fig. 3d).
Fig. 1 HOXB7-Cre; Vhlhfl/fl mice develop hemangiomas and fibrotic lesions in the liver. a Whole-mount (left) and H&E-stained section (right) of wild-type
mouse liver from a HOXB7-Cre; Vhlh+/+ mouse. b Whole-mount (left) and H&E-stained section (right) of knockout mouse liver from a HOXB7-Cre; Vhlhfl/fl
mouse. Hemangiomas are indicated by arrows and erythrocyte-filled blood vessels are indicated by asterisks (*; interpreted by a pathologist). c H&E-stained
liver section from a HOXB7-Cre; Vhlhfl/fl mouse. A cluster of leukocytes within the hemangioma is indicated by an arrow (interpreted by a pathologist). d
Liver section from a HOXB7-Cre; Vhlhfl/fl knockout mouse, stained for CD45 (a pan-leukocyte marker). A cluster of leukocytes near the blood
vessel is indicated (*; interpreted by a pathologist). e Whole-mount of liver from a HOXB7-Cre; Vhlhfl/fl knockout mouse. Fibrotic foci are
indicated by arrows. f H&E-stained section of liver from a HOXB7-Cre; Vhlhfl/fl knockout mouse. A large fibrotic site is indicated (*; interpreted by a
pathologist). g Representative images of whole-mounted livers of 3, 4 and 6-week old HOXB7-Cre; Vhlhfl/fl mice. The penetrance of hemangiomas at 3,
4, and 6 weeks of age is indicated in the table below the images. Numbers in brackets refer to mice with hemangiomas versus total mice
analyzed (n with hemangiomas/n total)
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Vhlh inactivation occurs in liver leukocytes, not in liver
parenchyma
Although the hemangioma phenotype recalled the out-
come of previous hepatocyte-specific Vhlh knockout
mice [20, 22], to our knowledge, the HOXB7-Cre driver
used in our study has not been shown to function in the
liver. We therefore used the ROSA-LacZ reporter [31] to
determine whether this Cre driver mediated gene inacti-
vation in the hepatocytes. As previously shown, Cre
activity was readily detected in cortex and medulla of
kidneys from HOXB7-Cre; Rosa-LacZ+ mice, whereas no
Cre activity was detected in kidneys of Cre-negative
ROSA-LacZ+ mice (Fig. 4a, left panel, compare Cre- and
Cre + kidney) [25, 28, 29]. In contrast, we observed no
overt Cre activity in the liver of HOXB7-Cre; ROSA-
LacZ+ mice (Fig. 4b). We also did not observe steatosis
in hepatocytes, a phenotype characteristic of Vhlh null
hepatocytes [20, 22] (data not shown). It should be noted
that the ROSA-LacZ locus is on the same chromosome as
the Vhlh locus; therefore the reporter could not be used
to trace Vhlh knockout cells. When an alternative and
more sensitive PCR method was used, Vhlh inactivation
was detectable in the livers of knockout mice. We used
previously published primers to detect the wild-type and
floxed Vhlh alleles [22], and designed new primers to de-
tect the recombined (deleted) Vhlh allele (see Methods
and Fig. 4c). Using these primers, we were able to de-
tect the recombined Vhlh allele (Vhlhdel) in the livers
of HOXB7-Cre; Vhlhfl/fl mice (Fig. 4d, lanes labeled with
KO). Confirming the specificity of the primers, no dele-
tion was detected in the livers of Cre-negative Vhlhfl/fl
littermates (Fig. 4d, lanes labeled with WT). We also
confirmed the identity of the Vhlhdel band by sequen-
cing (data not shown). Next, both hemangiomas and
gross-morphologically healthy looking liver tissue were
dissected out of livers of HOXB7-Cre; Vhlhfl/fl mice.
Interestingly, a much stronger signal for the deleted
allele was observed in hemangioma tissue compared to
Fig. 2 Extramedullary erythropoiesis in Vhlh knockout mice. a Erythrocyte progenitors are increased by ~10-fold in livers of HOXB7-Cre; Vhlhfl/fl
knockout mice. Liver cell suspensions were prepared by mincing livers, followed by collagenase digestion and treatment with red blood cell lysis
buffer (see Methods). Flow cytometric quantification of erythrocyte progenitors (TER119 + CD71+) was performed. Shown are representative FACS-plots (left
panels) and quantification (right panel). Gate was set on live CD45+ cells, and doublets were gated out. b Quantification of erythroid progenitors with
colony forming unit assay. Liver cell suspensions from HOXB7-Cre; Vhlhfl/fl (Vhlh-/-), HOXB7-Cre; Vhlhfl/fl; Hif2αfl/+ (Vhlh-/-; Hif2α+/-), HOXB7-Cre; Vhlhfl/fl; Hif2αfl/fl
(Vhlh-/-; Hif2α-/-), and Vhlhfl/fl (WT) mice were prepared and cultured as described in Methods. Left panel: Representative image of erythroid progenitor
colonies (BFU-E) from a Vhlh knockout mouse. Right panel: Quantification of BFU-Es. While Vhlh knockout increased the number of BFU-E compared to that
obtained from liver cell suspensions of Cre negative mice (WT), no difference was seen in the number of BFU-Es from WT and HOXB7-Cre Vhlh-Hif-2α double
knockouts. One Vhlh-/- and Hif-2α single allele knockout animal of the genotype HOXB7-Cre; Vhlhfl/fl; Hif-2αfl/+ (Vhlh-/-; Hif2α+/-) was used as a reference, which
showed increased BFU-E number as in the Vhlh knockout. Mice were >3 months old. p-values were calculated using Student’s t-test with
Welch’s correction. *: statistically significant (p < 0.05); ns: not significant
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adjacent normal liver tissue [Fig. 4d, compare lanes
labeled – (no hemangioma) and + (with hemangioma)],
indicating that Vhlh null cells were enriched in the
hemangiomas.
The lack of Cre + cells in wild-type liver, and enrichment
of Vhlh deletion allele in the hemangiomas of the knock-
outs raised the possibility that Vhlh deletion occurred in
an invading or locally expanded cell population. To deter-
mine in which cell type Vhlh was inactivated, we used an-
other Cre-reporter: the HOXB7-GFP-Cre driver that can
be combined with the Vhlh flox allele. In the HOXB7-
GFP-Cre driver, Gfp and Cre are made from a bicistronic
message, and GFP is readily detectable in the kidney
{Fig. 5a and [25, 29]}. Using this reporter, we detected
GFP expression in isolated, non-hepatic cells interspersed
in the liver parenchyma, and within the hemangiomas
(Fig. 5b, c). These cells appeared to be leukocytes. Indeed,
by PCR, Vhlh inactivation was detectable in leukocytes
(CD45+ fraction) isolated from hemangiomas by FACS
(Fig. 5d, e). The unrecombined floxed allele was also
Fig. 3 Inactivation of Hif-2α rescues extramedullary erythropoiesis and suppresses hemangiomas. a Erythropoietin is over-expressed in livers of
HOXB7-Cre; Vhlhfl/fl knockout mice: analysis of Erythropoietin (Epo) mRNA expression by quantitative PCR. b Serum erythropoietin levels were determined
by ELISA for indicated genotypes. Data were pooled from mice of >2 months of age. Erythropoietin was elevated by ~5 folds in the serum of HOXB7-
Cre; Vhlhfl/fl (Vhlh-/-) mice compared to HOXB7-Cre; Vhlh+/+ or Cre negative (WT) littermates. Upon Hif-2α inactivation (HOXB7-Cre; Vhlhfl/fl; Hif-2αfl/fl double
knockout) (Vhlh-/-; Hif2α-/-) serum erythropoietin levels returned to normal, compared with wild-type (WT). Hif-2α single allele knockout did not
significantly affect the Vhlh knockout Epo level (HOXB7-Cre; Vhlhfl/fl; Hif-2αfl/+) (Vhlh-/-; Hif2α+/-). Data were analyzed by Student’s t-test with
Welch’s correction for unequal variance, followed by Bonferoni post-test. c Erythroid progenitors (TER119 + CD71+) were isolated from hemangiomas
of two (labeled 1, 2) knockout mice with FACS (purity ~80 %). Genomic DNA was prepared and used for PCR for the recombined, the deleted Vhlh
allele (Vhlh del), and the floxed allele (Vhlh flox). No deleted allele was detected in these erythrocyte progenitors. As controls, PCR without
template (no template) and PCR with genomic DNA from liver of knockout mice (containing both deleted and floxed alleles; positive control) was
performed. d Hemangiomas were rescued in HOXB7-Cre; Vhlhfl/fl; Hif-2αfl/fl double knockouts. Hemangiomas were counted in H&E stained liver sections
of 2-3 months old mice of indicated genotypes. While the number of hemangiomas per liver section was significantly increased in Vhlh knockouts
compared to the wild-type, the number of hemangiomas was significantly decreased in HOXB7-Cre; Vhlhfl/fl; Hif-2afl/fl double knockout mice compared
with HOXB7-Cre; Vhlhfl/fl single knockouts. Each data point represents one liver sample. Counts were averaged from at least 5 sections per liver. p-values
were calculated using Student’s t-test with Welch’s correction. *: statistically significant (p < 0.05); ns: not significant
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detectable in this fraction (Fig. 5e), which is not surprising
since these leukocytes are heterogeneous, comprising B
cells, T cells, NK cells and myeloid cells (data not shown).
Of note, GFP is not detected in the endothelia (Fig. 5b, c),
and as shown above (Fig. 2d), the erythrocyte progenitors
isolated from the liver of knockout mice did not contain
Vhlh deletion allele, either. We therefore conclude that in
this mouse model, Vhlh is inactivated in a subset of liver
leukocytes.
Vhlh inactivation is detected in granulocytes/neutrophils
Hoxb7 expression has been observed in granulocytes iso-
lated from murine bone marrow [32]. This would agree
with our observation of Vhlh inactivation in leukocytes.
We therefore isolated granulocytes (CD11b + SSC-A
high) from liver hemangiomas by FACS (Fig. 6a) and
were able to detect Vhlh deletion consistently in the
granulocyte-enriched fraction (Fig. 6b). Vhlh inactivation
was also occasionally observed in the CD11b + SSC-A
medium/low fraction, a fraction that contains some
granulocytes besides other myeloid cells; and in the non-
myeloid fraction (Fig. 6b). The appearance of Vhlh dele-
tion in these non-granulocyte fractions is inconsistent; it
is therefore difficult to assess their functional signifi-
cance. Consistent with Vhlh inactivation, we also ob-
served significant up-regulation of the Hif-2α responsive
gene Phd3 in granulocytes (Fig. 6c). Taken together,
these data indicate that the HOXB7-Cre driver mediates
inactivation in a subset of granulocytes.
Among the HIF-dependent pro-angiogenic factors, we
have detected increased expression of vascular endothe-
lial growth factor B (VEGFB) and placental growth fac-
tor (Plgf ) in the liver of knockout mice (data not
shown). We used Plgf as a marker to examine the cell
type potentially contributing to the liver phenotype. As
shown in Fig. 7, both Plgf-positive and negative neutro-
phils could be observed (Fig. 7a, b). Interestingly, the
percentage of Plgf-positive neutrophils was significantly
increased (>10 folds) in the liver of knockout mice com-
pared with the wild-type (Fig. 7c).
Hepatic phenotypes were rescued by reconstitution with
wild-type hematopoietic stem cells
To elucidate the contribution of Vhlh null granulocytes
to hemangioma formation, we generated bone marrow
chimeras. Hematopoietic stem cells were enriched by
sorting the Hoechst-negative “side population” (SP) from
bone marrow (Fig. 8a) [26]. Lethally irradiated mice were
reconstituted with 1000 SP cells, and the chimerism—-
defined as percentage of peripheral blood leukocytes de-
rived from donor stem cells—was determined one
month (knockout recipients) or 2–6 months (wild-type
recipients) after transplantation to confirm the success
of the transplant (Fig. 8b). A chimerism of 60–80 % was
Fig. 4 HOXB7-Cre mediates deletion in liver leukocytes. a, b Rosa-LacZ reporter detects HOXB7-driven Cre expression in the kidney, but not in the
liver. a Kidney of Rosa-LacZ+ (Cre-) or HOXB7-Cre; Rosa-LacZ+(Cre+) was stained with β-galactosidase substrate. b Liver of HOXB7-Cre; Rosa-LacZ+
mouse. Left panels show gross morphological appearance of whole-mount stains (kidneys were sectioned in halves), and right panels show sections
prepared from whole-mounts. Strong LacZ signal is seen in medulla and cortex of HOXB7-Cre; Rosa-LacZ+ kidney (a), but not in Cre negative Rosa-LacZ+
kidney (a) or HOXB7Cre+; Rosa-LacZ+ liver (b). c Map of the floxed Vhlh allele (based on description by Haase et al. [20]) and locations of
primers for detection of wild-type and floxed Vhlh allele (FW1-Rev1, green; primers designed by Rankin et al. [22]) and recombined, deleted
allele (FW2-Rev2, red; primers design is as described in Methods). Not drawn to scale. FW, forward primer; Rev, reverse primer; 5′UTR, 5 prime
untranslated region; loxP, loxP site. d By PCR, Vhlh deletion is detected in livers of HOXB7-Cre; Vhlhfl/fl mice. Genomic DNA was isolated from
livers of HOXB7-Cre; Vhlhfl/fl (KO) mice and Cre negative littermates (WT). For each genotype, genomic DNA from three different mice (1–3) was
obtained. PCR was performed with primers specific for the wild-type (Vhlh wt), floxed (Vhlh flox) or recombined (deleted) (Vhlh del) alleles
using primers described in c. In addition, Cre-specific PCR was performed. Knockout DNA samples were isolated from either liver tissue with
healthy appearance (-) or liver tissue with hemangiomas (+). Note that the recombined Vhlh allele (Vhlh del) was only detected in knockout
mice, confirming the specificity of PCR. Furthermore, the signal for the recombined allele was much stronger in knockout liver tissue with
hemangiomas (+) compared to knockout liver tissue with healthy appearance (-). As controls, PCR was performed without template (no template) or
with liver DNA from a Vhlhfl/+ mouse (positive control for floxed and wild-type Vhlh alleles)
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obtained (Fig. 8c). Control experiments showed that
wild-type donor to wild-type recipient transplantation
did not cause any liver phenotype (Fig. 8c, d); and that
knockout donor to knockout recipient transplantation
generated liver hemangioma phenotype with severity
indistinguishable from the HOXB7-Cre; Vhlhfl/fl mice
(Fig. 8c, e). In the wild-type to knockout chimeric mice,
hemangiomas were rescued (Fig. 8c, f ) or improved
(Fig. 8c, g) in 50 % of knockout mice (Fig. 8c, h). The
partial rescue could be because the replacement of the
host hematopoietic stem cells (chimerism) was not
complete. However, it is also possible that other non-
bone marrow-derived components might be involved.
Interestingly, knockout to wild-type transplantation did
not generate the hemangioma phenotype, despite high
chimerism (Fig. 8c, i). This indicates that Vhlh inactiva-
tion in the hematopoietic component is necessary but
insufficient for the hemangioma formation.
Fig. 5 Deletion of Vhlh in liver leukocytes. a By immunohistochemistry, GFP is prominent in the collecting ducts in kidney of the reporter strain
HOXB7-GFP-Cre; Vhlhfl/fl [25, 29]. b, c GFP is also detectable in single cells interspersed within the liver parenchyma (b1) or within hemangiomas
(c2, 3). d Isolation of leukocytes from livers of HOXB7-Cre; Vhlhfl/fl mice. Liver cell suspensions were prepared by mincing livers, digesting with
collagenase, and lysing red blood cells with red blood cell lysis buffer. Liver cell suspensions were then stained with the pan-leukocyte marker
CD45 and propidium iodide (live/dead stain). Live CD45+ cells were isolated with FACS; debris and doublets were gated out. After the sort, CD45+ fractions
were >90 % pure. e By PCR, Vhlh inactivation was detected in CD45+ leukocyte fraction of 5 independent samples (1–5). Samples 3–5 were additionally
examined for the presence of floxed alleles (the amount of DNA samples 1 and 2 were insufficient for additional PCR tests). As control, PCR
was performed without template (no template control) or with genomic DNA from a HOXB7-Cre; Vhlhfl/fl knockout kidney (positive control,
which contains both Vhlh-inactivated and wild-type cells)
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Discussion
The kidney phenotype in HOXB7-Cre; Vhlhfl/fl knockout
mice develops at ~2 months of age {[25] and data not
shown}. In contrast, nascent hemangiomas are already
apparent in 75 % of 4-week old mice, and well-
developed hemangiomas are present in 90 % of 6-week
old mice (Fig. 1d). Furthermore, Hif-2α inactivation
ameliorates the hemangioma phenotype, but has no ef-
fect on the kidney phenotype. Thus, the liver phenotype
is most likely not the result of Vhlh inactivation in the
kidney lesion. We cannot exclude the possibility that
Hif-2α-induced factors emanating from the kidney are
required for liver hemangioma formation. However, this
explanation is not favored because other kidney-specific
Vhlh knockouts do not develop liver phenotype [11, 33].
Liver hemangiomas have been described previously in
germline Vhlh+/- mice and in mice with Vhlh inactivation
in hepatocytes (PEPCK-Cre or Albumin-Cre driven Vhlh
knockout mice) [20, 22, 23]. PEPCK-driven Cre is worth
noting because it has dual specificity in kidney (proximal
Fig. 6 Vhlh is deleted in granulocytes of HOXB7-Cre; Vhlhfl/fl mice. a Isolation of (1) non-myeloid cells (CD11b-), (2) other myeloid cells (CD11b +
SSCA low/medium), and (3) granulocytes (CD11b + SSCA high) from HOXB7-Cre; Vhlhfl/fl mice by FACS. Shown are representative FACS-plots before
and after sorting. The three populations are indicated in each panel. b PCR analysis of Vhlh alleles in genomic DNAs isolated from the above cell
populations. Recombined Vhlh allele (Vhlh del) is consistently observed in (3) granulocyte-enriched fraction (~95 % CD11b+, 70 % CD11b + SSCA
high). As control, PCR was performed without template (no template control) or with genomic DNA from the liver of a HOXB7-Cre; Vhlhfl/+ mouse
(positive control containing Vhlh-floxed and wild-type cells) or a HOXB7-Cre; Vhlhfl/fl kidney (positive control containing Vhlh-del cells). c Consistent
with Vhlh inactivation, the mRNA of Proline-hydroxylase 3 (Phd3), a Hif-2α-responsive gene, is up-regulated in the granulocyte fraction, as assayed by qPCR
Fig. 7 Plgf is expressed in neutrophils of HOXB7-Cre; Vhlhfl/fl knockout mice. a, b Plgf immunohistochemistry of liver sections (brown stain). Nuclei
were stained with hematoxylin (light blue). Representatives Plgf + (a) and Plgf- (b) neutrophils localized within hemangiomas of a HOXB7-Cre;
Vhlhfl/fl knockout mouse are shown. Note the polymorpho-nuclear shape characteristic of neutrophils. c Quantification of Plgf-expressing liver neutrophils
(immunohistochemistry); n= 3 mice per group, total number of neutrophils counted: 38 (WT) and 510 (KO). Neutrophils were classified as strongly Plgf
positive (Plgf+, dark pink), weakly Plgf positive (Plgf+/-, white) or Plgf negative (Plgf-, grey). A ~10-fold increase in the percentage of Plgf + neutrophils was
observed in HOXB7-Cre; Vhlhfl/fl mice compared to Cre-negative littermates (46 % versus 4.4 %)
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Fig. 8 Hemangiomas in knockout mice are partially rescued by reconstitution with wild-type hematopoietic stem cells. Hematopoietic stem cells
were enriched by sorting Hoechst negative side population (SP) from bone marrow. 8–9-week old wild-type mice or 4-week old HOXB7-Cre;
Vhlhfl/fl mice were lethally irradiated and transplanted with 1000 SP obtained from 2 to 3 month old HOXB7-Cre; Vhlhfl/fl mice (KO), or Cre-negative
Vhlhfl/fl littermates (WT). a Representative Hoechst stain followed by sorting. Percentage of Hoechst negative cells is indicated. Only the tip of the
Hoechst negative tail that contains cells with the least Hoechst fluorescence was collected. b Representative flow data of peripheral blood
leukocytes stained with CD45.1 and CD45.2 two months after the transplant (wild-type recipients) or one month after the transplant (HOXB7-Cre; Vhlhfl/fl
recipients). Recipients were CD45.1/2 double positive and were transplanted with CD45.1 single positive SP. c Summary of transplant experiments.
d–i Representative phenotypes of the transplanted chimera. Livers of KO recipients were obtained one month after the transplant, at ~2 months of
age; livers of WT recipients were obtained at 2, 3 and 6 months after transplantation. Numbers beneath images indicate number of mice with
phenotype versus total number of mice analyzed. d Wild-type SP to wild-type recipients (WT - > WT) did not show any phenotype. e Knockout
SP to knockout recipients (KO - > KO) showed full-penetrant phenotype. f–h Hemangiomas are partially rescued in HOXB7-Cre; Vhlhfl/fl recipient
mice (KO) transplanted with SP from Cre negative Vhlhfl/fl mice (WT). i Knockout SP to wild-type recipients (KO - > WT) showed no phenotype
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tubules) and liver (~20–30 % hepatocytes) [22]. Here, we
show that HOXB7-Cre driven Vhlh conditional knockout
mice also develop hemangiomas in the liver, although
unlike previous models, this Cre driver does not mediate
recombination in hepatocytes. We were unable to detect
Cre activity in hepatocytes using the Rosa-LacZ reporter,
and we also did not observe steatosis in hepatocytes, a
phenotype characteristic of Vhlh null hepatocytes [20, 22].
The more hepatocyte-specific Cre (Albumin-Cre) driven
Vhlh knockout also generated hemangiomas, albeit more at
the microscopic level [22]. However, despite superficial
similarity of the phenotypes, several findings indicate that
the mechanism of hemangioma formation is different in
hepatocyte-specific Albumin-Cre driven and HOXB7-Cre
driven Vhlh knockout mice. In HOXB7-Cre driven Vhlh
knockout mice, hemangiomas develop with higher pene-
trance (90 % vs ~40 %) and at a younger age (4–6 weeks
versus ~3–8 months) compared to the Albumin-Cre Vhlh
knockout mice [20]. Furthermore, the hemangiomas in
HOXB7-Cre driven Vhlh knockouts exhibit extramedullary
hematopoiesis that is also observed in human hemangio-
blastoma but not in liver with hepatocyte Vhlh knockout
(either Albumin-Cre or PEPCK-Cre driven).
Another difference between the hepatocyte-specific
Vhlh knockout mice and the HOXB7-Cre driven Vhlh
knockout mice is the pattern of erythropoiesis. Erythro-
poietin is over-expressed in the knockout mice with
hepatocyte-specific Vhlh inactivation [20, 22], as well
as in HOXB7-Cre driven Vhlh knockout mice. However,
while erythropoietin over-expression induced systemic
erythrocytosis—characterized by elevated hematocrit—in
PEPCK-Cre and Albumin-Cre driven Vhlh knockout mice
[20, 22], erythropoiesis was only increased in HOXB7-Cre
driven Vhlh knockout mice in specific organs such as liver.
There is no increase in hematocrit in HOXB7-Cre driven
Vhlh knockouts (data not shown). This pattern of focal
erythropoiesis resembles the pattern observed in VHL
patients, who develop polycythemia only rarely, despite
tumor-associated extramedullary erythropoiesis [34].
By PCR, a stronger signal for the recombined allele
was detected in hemangiomas compared to healthy liver
tissue, indicating that Vhlh null cells are enriched in hem-
angiomas. Also, Cre activity was undetectable with the
Rosa-LacZ reporter in mice with wild-type Vhlh. Thus,
Vhlh inactivation likely occurs in a cell type that is rare in
the healthy liver and undergoes expansion or is recruited
to the liver when Vhlh is inactivated.
One type of cells that was enriched in hemangiomas is
leukocytes. We detected foci of leukocytes (CD45+) ad-
jacent to hemangiomas, and by PCR we detected Vhlh
inactivation in leukocytes isolated from hemangiomas
(Fig. 5). We further identified granulocytes/neutrophils
as the Vhlh mutant cells in this model (Figs. 6 and 7).
Furthermore, hemangiomas were partially rescued in
HOXB7-Cre; Vhlhfl/fl mice reconstituted with wild-
type hematopoietic stem cells (Fig. 8). Thus, Vhlh
inactivation in bone marrow-derived leukocytes contributes
to hemangioma formation in this mouse model. Interest-
ingly, Vhlh null leukocytes were not sufficient to induce
hemangiomas, since no hemangiomas were observed in the
reverse experiment (wild-type mice reconstituted with
HOXB7-Cre; Vhlhfl/fl hematopoietic stem cells). Thus, in-
activation of Vhlh in at least one other cell type besides
bone marrow-derived cells is required for hemangioma
formation. It may be that HOXB7-Cre driven Vhlh knock-
out in kidney tubule cells contributes to systemic elevation
of Epo, which in turn is required for hemangioma for-
mation in the liver. However, kidney hyperplasia and
tubule defects were rescued by inactivation of Hif-1α,
but not Hif-2α [25], whereas other kidney-specific Vhlh
knockout mouse models did not develop liver
hemangioma [11, 33]. The other contributing cell types
might include embryonic hematopoietic progenitor cells
in the liver that fail to migrate to the bone marrow. How-
ever, we did not detect Vhlh deletion in the erythrocyte
progenitor cells, despite increased number of these pro-
genitors. We did, however, detect Vhlh deletion in liver
granulocytes/neutrophils and moderately increased num-
ber of Granulocyte/Macrophage/Megakaryocyte/Erythroid
(GMME) progenitors cells in the liver (data not shown).
This indicates that Vhlh mutant liver-resident granulo-
cyte progenitors may be critical for liver extramedullary
erythropoiesis and hemangioma formation. Interestingly,
it has been reported that VHL haploid insufficiency in
neutrophils contributes to their decreased apoptosis, and
thus population expansion, in VHL patients. It may be
that liver resident granulocytes/neutrophils undergo ex-
pansion and promote angiogenesis. We indeed observed
increased population of Plgf-expressing neutrophils in
knockout mice compared to wild-type. Therefore both
bone marrow-derived and liver-resident granulocytes/
neutrophils are needed for the full penetrance of liver
hemangioma phenotype.
We have not observed the hemangioma phenotype in
other organs of the Vhlh knockout mice described here.
This indicates that a unique hepatic microenvironment
may be required. However, since the kidney defects ob-
served in the Hoxb7-Cre; Vhlhfl/fl knockout mice include
hyper-vascularization and hemorrhage [25], it is tempting
to speculate that the activated neutrophils may also contrib-
ute to the full extent of the kidney hyperplastic phenotypes.
Future studies should address this intriguing possibility.
The finding that Vhlh null granulocytes contribute to
hemangioma formation is of significance for understand-
ing hemangioblastoma and other highly vascularized
VHL tumors. Since VHL patients are heterozygous for
VHL loss-of-function mutations, it is conceivable that in-
activation of the remaining wild-type allele could occur in
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more than one cell type (as indeed it does, since patients
are prone to develop tumors in several tissues), including
those constituting the stromal compartments. Mutations
in the cancer stromal cells have been documented that
contribute to cancer progression {reviewed in [12]}. In
particular, neutrophils have been recognized as a major
inducer of tumor angiogenesis [35]. Significantly, recent
reports have identified CXCR4 (a known HIF target)-ex-
pressing neutrophils as a highly pro-angiogenic subtype of
neutrophils [36]. It is therefore possible that in VHL
patients, VHL inactivation occurs in components of the
tumor microenvironment in addition to the tumor itself.
Pro-angiogenic VHL null granulocytes/neutrophils could
therefore contribute to the development of the tumor
vasculature.
Conclusions
Hemangioblastoma is a serious tumor associated with the
VHL disease and is difficult to study because of a lack of
animal models. One interesting pathological feature of this
disorder is that the endothelial cells are themselves geno-
mically normal. Instead, vascular overgrowth is induced by
adjacent non-endothelial cells that exhibit loss of heterozy-
gosity and may be of hematopoietic or embryonic origin.
Our mouse model shows that Vhlh inactivation in the
“stromal” (non-tumor) cell population, at least in part con-
sisting of granulocytes/neutrophils, can induce abnormal
angiogenesis. Furthermore, we show that hemangioma-
associated extramedullary erythropoiesis can occur without
Vhlh inactivation taking place in erythrocytes. This system
thus represents a good model for studying aspects of the
hemangioblastoma found in the human VHL disease.
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